As one of the Dutch papers put it overnight, Organon (a legacy Schering-Plough acquisition) is seeking a "restart" -- with a new parent, based in Europe -- one other than New Merck:
. . . .Pharmaceuticals company Organon wants owners Merck to sell the company rather than move its R&D unit to the US and shut down its production lines, according to anonymous sources in Friday's Financieele Dagblad.
Organon is a niche player in women's health, producing contraceptive pills, fertility treatments and hormones. It was taken over by pharmaceuticals giant Merck in 2009.
According to the sources, there are a few companies in Europe active in women's health that would be a good match for Organon.
The company [MSD] declined comment. . . .
This sort of less-than-flattering patter will almost certainly roll on in the papers in Europe well into the fall.
